Bond.az White LogoBond.az Black Logo
→
EN ▾
AZENRU
First in WUF history: Azerbaijan initiates WUF13 NGO Forum16-year-old Turkish footballer dies in crashMGE Energy Declares $0.475 Quarterly DividendNexstar president sells $46,539 in stockOstrover sells Commanders stake to HarrisAzerbaijan prepares to become regional hub for AI and data centersAttack on MK editorial office in MoscowTruist Raises Acushnet Target to $97Turkey to benefit from Azerbaijan's COP31 experienceBill.com price target cut to $45 on take rate outlookFirst in WUF history: Azerbaijan initiates WUF13 NGO Forum16-year-old Turkish footballer dies in crashMGE Energy Declares $0.475 Quarterly DividendNexstar president sells $46,539 in stockOstrover sells Commanders stake to HarrisAzerbaijan prepares to become regional hub for AI and data centersAttack on MK editorial office in MoscowTruist Raises Acushnet Target to $97Turkey to benefit from Azerbaijan's COP31 experienceBill.com price target cut to $45 on take rate outlook
Personalize
Bond.az White LogoBond.az Black Logo
AZENRU
TRANSCRIPTS

Stellus Capital Q1 2026 EPS Meets Forecast, Revenue Misses

Stellus Capital Q1 2026 EPS meets forecast at $0.26, but revenue misses at $23.29M. Stock drops 3.69%. Portfolio at $990M.

Alexander Gonzalez
ByAlexander Gonzalez- Senior Editor
|
0
Stellus Capital Q1 2026 EPS Meets Forecast, Revenue Misses
Photo: Prepared by Bond.az

Stellus Capital Investment Corporation (SCM) reported mixed Q1 2026 results. EPS of $0.26 met forecasts, but revenue of $23.29 million missed the $24.91 million estimate. The stock fell 3.69% to $9.39 post-earnings.

The portfolio stood at $990 million, slightly down from the previous quarter. The company maintains focus on the lower middle market.

CEO Robert Ladd highlighted opportunities from the Ridgepost Capital partnership. Dividends are expected to align with net investment income over time.

More News
Vallourec Q1 2026 Beats Forecasts, Stock Fluctuates
Today / 14:40
|
851

Vallourec Q1 2026 Beats Forecasts, Stock Fluctuates

Vallourec Q1 2026 earnings beat forecasts; stock sees volatility. Strong EBITDA and cash flow highlight performance.

TRANSCRIPTS →
0
Home Depot Q1 2026 earnings beat forecasts, stock dips
Today / 14:20
|
888

Home Depot Q1 2026 earnings beat forecasts, stock dips

Home Depot Q1 2026 earnings beat forecasts with EPS of $3.43 and revenue of $41.8B. Stock dips 2.49% amid margin concerns.

TRANSCRIPTS →
0
Hera Group Q1 2026: Steady growth
Today / 14:03
|
352

Hera Group Q1 2026: Steady growth

Hera Group posts steady growth in Q1 2026 with net profit of EUR 155 million and EPS of $0.105.

TRANSCRIPTS →
0
Oxford Lane Capital NAV drops, stock dips
Today / 14:02
|
259

Oxford Lane Capital NAV drops, stock dips

Oxford Lane Capital Corp reports Q4 FY2026 results: NAV per share down, stock falls 4.03%. CLO yields decline. Read more on challenges and outlook.

TRANSCRIPTS →
0
Driven Brands Q4 2025 Revenue Growth Reported
Today / 13:43
|
246

Driven Brands Q4 2025 Revenue Growth Reported

Driven Brands Q4 2025 revenue grows 7.7% to $460.1M, EPS $0.34. Stock up 1.12%.

TRANSCRIPTS →
0
Ceragon Q1 2026 Revenue Beats Estimates
Today / 13:41
|
777

Ceragon Q1 2026 Revenue Beats Estimates

Ceragon Networks Q1 2026 revenue beat estimates at $85M. EPS $0.01. Stock rose 6.77% premarket. Full-year guidance reiterated.

TRANSCRIPTS →
0
Fractyl Health Q1 2026 EPS Beat, Shares Surge 23%
Today / 13:10
|
739

Fractyl Health Q1 2026 EPS Beat, Shares Surge 23%

Fractyl Health Q1 2026 EPS beat expectations by 76%, shares surged 23% after hours. Revita program data expected in Q4 2026.

TRANSCRIPTS →
0
Antalpha Q1 2026: EPS Misses Forecast, Stock Rises
Today / 13:01
|
272

Antalpha Q1 2026: EPS Misses Forecast, Stock Rises

Antalpha Q1 2026: EPS misses forecast at $0.07, stock rises 2.42%. Revenue up 52% to $20.7M. Web3 AI agent Nina launched. Q2 guidance $11M-$13M.

TRANSCRIPTS →
0
GNFC Q4 profit surges, stock climbs 5.17%
Today / 12:44
|
314

GNFC Q4 profit surges, stock climbs 5.17%

GNFC Q4 FY2026 strong results: revenue up 11%, PAT up 35%, stock rises 5.17%. Chemical segment drives growth.

TRANSCRIPTS →
0
Relmada TX Q1 2026: Loss and stock dip
Today / 12:42
|
677

Relmada TX Q1 2026: Loss and stock dip

Relmada Therapeutics Q1 2026 results: stock declines, strong cash position and NDV-01 program in focus.

TRANSCRIPTS →
0
Inovio Beats Q1 2026 EPS Forecast, Stock Slips
Today / 12:00
|
959

Inovio Beats Q1 2026 EPS Forecast, Stock Slips

Inovio Q1 2026 EPS beats forecasts, but stock falls. Detailed financial analysis and outlook on Bond.az.

TRANSCRIPTS →
0
CytoSorbents Q1 2026 Misses Forecasts, Stock Falls
Today / 11:50
|
449

CytoSorbents Q1 2026 Misses Forecasts, Stock Falls

CytoSorbents Q1 2026 results: EPS of -$0.05 misses estimate, revenue of $8.9M falls short, stock drops 7.53%. Company cuts costs and targets breakeven in H2 2026.

TRANSCRIPTS →
0
...